|
Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study. |
|
|
Consulting or Advisory Role - Genomic Health; IntegraConnect |
Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; Dendreon; Janssen Oncology; Sanofi |
|
|
Honoraria - Dendreon; Janssen Oncology; Sanofi |
Consulting or Advisory Role - Bayer; Dendreon; Janssen Biotech; Medivation; Novartis; Pfizer; Sanofi |
Speakers' Bureau - Dendreon; Sanofi |
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst) |
Travel, Accommodations, Expenses - Dendreon; Janssen Biotech; Medivation; Sanofi |
|
|
Stock and Other Ownership Interests - Swan Valley Medical |
Honoraria - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation/Astellas |
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation/Astellas |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Medivation |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Janssen (Inst); Medivation/Astellas (Inst); Spectrum Pharmaceuticals |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; dendreon; Janssen; Medivation/Astellas; Spectrum Pharmaceuticals |
|
|
Employment - Astellas Pharma |
|
|
Consulting or Advisory Role - Astellas Pharma |
|
|
Research Funding - Astellas Medivation (Inst); BHR Pharma (Inst); Churchill Pharmaceuticals (Inst); Dendreon (Inst); Eleven Biotherapeutics (Inst); Ferring (Inst); Janssen Oncology (Inst); Myovant Sciences (Inst); pfizer (Inst); Siemens (Inst) |
|
|
Consulting or Advisory Role - Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Novartis; Pfizer |
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst) |
|
|
Employment - QuintilesIMS |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
Employment - Astellas Pharma |
|
|
Stock and Other Ownership Interests - Egenix; Exelixis (I) |
Research Funding - Advantagene (Inst); Dendreon (Inst); Medivation (Inst) |
Other Relationship - American Urological Association |
|
|
Employment - Astellas Pharma |
|
|
Employment - QuintilesIMS |
|
|
No Relationships to Disclose |
|
|
Employment - QuintilesIMS |
|
|
Consulting or Advisory Role - Astellas Pharma; Dendreon |
Research Funding - Astellas Pharma (Inst); Medivation (Inst) |